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Background: Although patients with peripheral arterial disease are at increased risk of cardiovascular morbidity and mortality, evidence based 
medical therapy (EBMT) is underused in these patients. Prior studies have documented poor adherence to such therapy among patients who have 
undergone revascularization.
objective: We evaluated the impact of prescription of EBMT prior to discharge after peripheral vascular intervention (PVI) on overall medication 
compliance in a large multi-specialty, multi-center quality improvement collaborative.
methods: 14,105 patients undergoing PVI between 1/1/2008 and 12/31/2011 were included. Post-PVI discharge and six month medication 
compliance in patients on ASA, beta-blocker (BB) and statin were compared. In addition, clinical outcomes were compared for patients receiving 
each of the three drugs post-PVI to those that did not.
results:  12,947 (92%) patients were prescribed ASA, 9,788 (69%) BB and 11,609 (82%) statins. Post-procedural use was associated (all 
p<0.001) with reported six month use: ASA (84.5% vs 39.2%), BB (82.5% vs 11.1%) and statin (84.6% vs 21.8%). No differences in mortality or MI 
at 6 months was observed.
conclusions: Prescribing EBMT at the time of PVI is associated with excellent compliance at 6 months, while failure to prescribe EBMT at 
discharge is associated with low use at 6 months. This data suggest that the time of a PVI is a therapeutic window to prescribe EBMT in this high-risk 
cohort and represents an opportunity for quality improvement.
 
